AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. In Finland AstraZeneca employs 100 people.
Solving the challenges facing sustainable healthcare requires broad collaboration. AstraZeneca is committed to fostering transformative collaboration, well exemplified by our BioVentureHub in Gothenburg, Sweden. An open innovation platform, the hub co-locates biotechs, medtechs, and digital health startups alongside AstraZeneca’s
scientists, creating an environment where shared expertise, infrastructure, and real-world insights accelerate innovation in healthcare.
AstraZeneca’s membership in CleverHealth Network is a logical continuation stemming from this commitment.
“At AstraZeneca, we want to be a key partner in developing sustainable healthcare in Finland. Digital health and health data will play a key part in this, which is why we are thrilled to be a part of CleverHealth Network”, says Klaus Tamminen, Medical Head, AstraZeneca Finland.
Read more about AstraZeneca at www.astrazeneca.com.
